GeoVax Labs Inc. (NASDAQ: GOVX)
$2.96
+0.1500 ( +5.34% ) 4.0M
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy againstĀ head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors.
Market Data
Open
$2.96
Previous close
$2.81
Volume
4.0M
Market cap
$7.48M
Day range
$2.82 - $3.55
52 week range
$1.09 - $10.24
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
10-k/a | Quarterly Reports | 17 | Mar 11, 2024 |
8-k | 8K-related | 17 | Mar 01, 2024 |
10-k | Annual reports | 68 | Feb 29, 2024 |
4 | Insider transactions | 1 | Feb 22, 2024 |
8-k | 8K-related | 15 | Feb 16, 2024 |
4 | Insider transactions | 1 | Feb 07, 2024 |
8-k | 8K-related | 19 | Jan 31, 2024 |
8-k | 8K-related | 13 | Jan 16, 2024 |
4 | Insider transactions | 1 | Dec 26, 2023 |
8-k | 8K-related | 13 | Dec 08, 2023 |